The Development and Regulation of Psychedelic Medicines


Psychedelic research into mental disorders is currently re-emerging after a near 40-year morass and appears to offer a new paradigm of treatment for civilians and veterans suffering from mental disorder and/or addiction. The paper introduces the recent rebirth of psychedelic research at a small number of US and European universities such as Johns Hopkins, New Mexico, Zurich, UCLA, NYU, Imperial College London as well as at non-academic bodies with research into substances such as MDMA, psilocybin, LSD, THC and CBD in marijuana, ketamine, DMT (found in ayahuasca) and ibogaine. The legal impediments to psychedelic research and regulation are discussed including international drug conventions, drug scheduling, medicine regulation and the patent system. The paper considers the controversial nature of the research and its implications which could drive significant medical change through new forms of treatment for mental disorder and addiction

Similar works

Full text


Northumbria Research Link

Provided original full text link
oaioai:nrl.northumbria.ac.uk:31696Last time updated on 10/20/2017

This paper was published in Northumbria Research Link.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.